Literature DB >> 29259733

Editorial for Cancer Virtual Issue.

Benjamin E Blass1.   

Abstract

Entities:  

Year:  2017        PMID： 29259733      PMCID： PMC5733273          DOI： 10.1021/acsmedchemlett.7b00472

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  24 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

Authors:  V M Richon; X Zhou; R A Rifkind; P A Marks
Journal:  Blood Cells Mol Dis       Date:  2001 Jan-Feb       Impact factor: 3.039

Review 3.  Pralatrexate: basic understanding and clinical development.

Authors:  Jasmine Zain; Owen O'Connor
Journal:  Expert Opin Pharmacother       Date:  2010-07       Impact factor: 3.889

Review 4.  Capecitabine: A new oral fluoropyrimidine.

Authors:  R J Ignoffo
Journal:  Cancer Pract       Date:  1998 Sep-Oct

5.  Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).

Authors:  J C Marsh; R C DeConti; S P Hubbard
Journal:  Cancer Chemother Rep       Date:  1971-12

Review 6.  Cobimetinib.

Authors:  Jessie Signorelli; Arpita Shah Gandhi
Journal:  Ann Pharmacother       Date:  2016-10-04       Impact factor: 3.154

Review 7.  Genetics of familial melanoma: 20 years after CDKN2A.

Authors:  Lauren G Aoude; Karin A W Wadt; Antonia L Pritchard; Nicholas K Hayward
Journal:  Pigment Cell Melanoma Res       Date:  2015-01-05       Impact factor: 4.693

Review 8.  Irinotecan (CPT-11): pharmacology and clinical applications.

Authors:  N Masuda; S Kudoh; M Fukuoka
Journal:  Crit Rev Oncol Hematol       Date:  1996-09       Impact factor: 6.312

Review 9.  Romidepsin: a novel histone deacetylase inhibitor for cancer.

Authors:  Erin M Bertino; Gregory A Otterson
Journal:  Expert Opin Investig Drugs       Date:  2011-06-24       Impact factor: 6.206

Review 10.  AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

Authors:  E Weisberg; P Manley; J Mestan; S Cowan-Jacob; A Ray; J D Griffin
Journal:  Br J Cancer       Date:  2006-05-23       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.